by Dr. Ed Weber | May 17, 2022 | PCa Commentary
[Prostate Cancer Commentary Vol. 143 PCa Commentary #143: ANTI-PSMA 177-LUTETIUM RADIOLIGAND THERAPY discusses the mechanism of action of 177Lu therapy, its background and outcome of early studies] (control+click above link to follow or visit...
by Dr. Ed Weber | Apr 19, 2022 | PCa Commentary
When the PSA is elevated following initial potentially curative treatment with prostatectomy or radiation therapy, the customary management response has been hormone suppression with Lupron, Degarilix or Relugolix. This Commentary highlights an alternative...
by Dr. Ed Weber | Mar 10, 2022 | PCa Commentary, Uncategorized
Heterogeneity is the Achilles heel of prostate cancer staging. Intermediate-risk cancers with Gleason Score 3+4 and 4+3 (i.e., Grade Groups 2 and 3) are especially fraught with this complexity. A report, “Molecular Analysis of Low-Grade Prostate Cancer Using...
by Dr. Ed Weber | Feb 3, 2022 | PCa Commentary, Uncategorized
[A prior Commentary, Vol. 138, September 2019 https://www.prostatecancerfree.org/pca-commentary-138-active-surveillance-update-and-new-developments/ covered this topic and remains current. This Commentary will build upon it.] Guidelines suggesting ‘best practice’...
by Dr. Ed Weber | Jan 21, 2022 | PCa Commentary
The BAT regimen was introduced in January 2015 in a report by Schweizer and his Johns Hopkins colleagues, “Effect of Bipolar Androgen Therapy for asymptomatic men with castration-resistant prostate cancer,” (Sci Transl Med). In their study, 16 men with low to moderate...